Foghorn Other Current Liab from 2010 to 2025

FHTX Stock  USD 4.31  0.11  2.62%   
Foghorn Therapeutics Other Current Liabilities yearly trend continues to be fairly stable with very little volatility. Other Current Liabilities is likely to outpace its year average in 2025. During the period from 2010 to 2025, Foghorn Therapeutics Other Current Liabilities regression line of annual values had r-squared of  0.63 and arithmetic mean of  3,409,447. View All Fundamentals
 
Other Current Liabilities  
First Reported
2010-12-31
Previous Quarter
9.7 M
Current Value
10.2 M
Quarterly Volatility
3.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Foghorn Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Foghorn Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 12.8 M, Interest Income of 12.8 M or Depreciation And Amortization of 3.9 M, as well as many indicators such as Price To Sales Ratio of 8.66, Dividend Yield of 0.0 or Days Sales Outstanding of 66.4 K. Foghorn financial statements analysis is a perfect complement when working with Foghorn Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Foghorn Therapeutics Correlation against competitors.
For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn Therapeutics guide.

Latest Foghorn Therapeutics' Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of Foghorn Therapeutics over the last few years. It is Foghorn Therapeutics' Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Foghorn Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Slightly volatile
   Other Current Liab   
       Timeline  

Foghorn Other Current Liab Regression Statistics

Arithmetic Mean3,409,447
Geometric Mean2,316,824
Coefficient Of Variation95.99
Mean Deviation2,685,115
Median1,445,000
Standard Deviation3,272,749
Sample Variance10.7T
Range9.7M
R-Value0.79
Mean Square Error4.2T
R-Squared0.63
Significance0.0002
Slope545,725
Total Sum of Squares160.7T

Foghorn Other Current Liab History

202510.2 M
20249.7 M
20238.4 M
2022M
20212.6 M
20205.2 M
2019450 K

About Foghorn Therapeutics Financial Statements

Foghorn Therapeutics investors use historical fundamental indicators, such as Foghorn Therapeutics' Other Current Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Foghorn Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Liabilities9.7 M10.2 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Foghorn Stock Analysis

When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.